logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10167472 B1

PDFFull Text
Expired
Date of Patent:
Jan. 01, 2019

Filed:

Apr. 14, 2017

Pme-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of pme-1 to inhibit epithelial to mesenchymal transition

Applicant:

Medical Diagnostic Laboratories, L.l.c., Hamilton, NJ (US);

Inventors:

Lyndi Rice, Philadelphia, PA (US);

Michelle Pusey, Bordentown, NJ (US);

Ewa Wandzioch, Wyndmoor, PA (US);

Sophie Marie Genevieve Bail, Princeton, NJ (US);

Amy Lynn Wenda, North Brunswick, NJ (US);

Assignee:

Medical Diagnostic Laboratories, LLC, Hamilton, NJ (US);

Attorneys:

Terence J. Bogle

Jessica Downing

Primary Examiner:

Sean McGarry

Int. Cl.
CPC ...
A61K 31/70 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 31/713 (2006.01); A61K 31/7105 (2006.01); C12N 5/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); C12Q 1/6886 (2013.01); C12Y 301/01089 (2013.01); G01N 33/57442 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/918 (2013.01);
Abstract

Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.

Find Patent Forward Citations

Quick Actions:

Rice, Lyndi. (2019). Pme-1 as a biomarker to predict and diagnose an increased risk of endometrial cancer and gene silencing of pme-1 to inhibit epithelial to mesenchymal transition (U.S. Patent No. 10167472). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10167472

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…